230 related articles for article (PubMed ID: 26046338)
41. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
42. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity.
Bell M; Milstein R; Beam-Goulet J; Lysaker P; Cicchetti D
J Nerv Ment Dis; 1992 Nov; 180(11):723-8. PubMed ID: 1431824
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
44. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
45. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
46. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
47. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
[TBL] [Abstract][Full Text] [Related]
48. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
49. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
51. An excitement subscale of the Positive and Negative Syndrome Scale.
Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
[TBL] [Abstract][Full Text] [Related]
52. Audio-digital recordings to assess ratings reliability in clinical trials of schizophrenia.
Targum SD; Pendergrass JC; Murphy C
Schizophr Res; 2021 Jun; 232():54-60. PubMed ID: 34015556
[TBL] [Abstract][Full Text] [Related]
53. Patient-based and clinician-based support for the remission criteria in schizophrenia.
Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
[TBL] [Abstract][Full Text] [Related]
54. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
Schimmelmann BG; Mehler-Wex C; Lambert M; Schulze-zur-Wiesch C; Koch E; Flechtner HH; Gierow B; Maier J; Meyer E; Schulte-Markwort M
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):768-78. PubMed ID: 18315449
[TBL] [Abstract][Full Text] [Related]
55. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis.
Zhu Y; Li C; Huhn M; Rothe P; Krause M; Bighelli I; Schneider-Thoma J; Leucht S
Eur Neuropsychopharmacol; 2017 Sep; 27(9):835-844. PubMed ID: 28669774
[TBL] [Abstract][Full Text] [Related]
56. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
[TBL] [Abstract][Full Text] [Related]
57. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Ogyu K; Noda Y; Yoshida K; Kurose S; Masuda F; Mimura Y; Nishida H; Plitman E; Tarumi R; Tsugawa S; Wada M; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):138-149. PubMed ID: 32180369
[TBL] [Abstract][Full Text] [Related]
58. The successful concurrent use of two long-acting depot antipsychotics in a patient with treatment-resistant schizophrenia and history of serious violence: a case report.
Lenardon A; Ahmed M; Harfield KL; Das M
Australas Psychiatry; 2017 Apr; 25(2):181-184. PubMed ID: 27879426
[TBL] [Abstract][Full Text] [Related]
59. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.
Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Degner D; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Eur Psychiatry; 2009 Dec; 24(8):501-6. PubMed ID: 19559572
[TBL] [Abstract][Full Text] [Related]
60. How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.
Samara MT; Nikolakopoulou A; Salanti G; Leucht S
Schizophr Bull; 2019 Apr; 45(3):639-646. PubMed ID: 29982701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
